Prognostic role of miR-17-92 family in human cancers: evaluation of multiple prognostic outcomes

Feifei Liu, Feng Zhang, Xiangyu Li, Qi Liu, Wei Liu, Peng Song, Ziying Qiu, Yu Dong and Hao Xiang _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:69125-69138. https://doi.org/10.18632/oncotarget.19096

Metrics: PDF 1552 views  |   HTML 2654 views  |   ?  


Feifei Liu1,2, Feng Zhang1,2, Xiangyu Li1,2, Qi Liu1,2, Wei Liu1,2, Peng Song1,2, Ziying Qiu1,2, Yu Dong1,2 and Hao Xiang1,2

1Department of Global Health, School of Health Sciences, Wuhan University, Wuhan, 430071, China

2Global Health Institute, Wuhan University, Wuhan, 430071, China

Correspondence to:

Hao Xiang, email: [email protected]

Keywords: miR-17-92 family, cancer, prognosis, meta-analysis

Received: May 02, 2017     Accepted: June 20, 2017     Published: July 08, 2017


Recent evidence indicates that miR-17–92 family might be an essential prognostic biomarker for human cancers. However, results are still inconsistent. We therefore performed a meta-analysis to evaluate the predictive role of miR-17–92 family in human cancer prognosis. We searched literatures published before March 31th, 2017 inPubMed, Cochrane and Embase databases. Twenty six studies were included in our analyses. The overall hazard ratios (HRs) showed that high expression level of miR-17-92 family was a predictor of poor overall survival (OS): adjusted HRs = 1.71, 95% confidence intervals (CIs): 1.39–2.11, p < 0.00001, and poor disease-free survival (DFS): adjusted HRs = 2.29, 95% CIs: 1.41–3.72, p = 0.0008. However, no association between miR-17-92 family expression and cancer progress-free survival (PFS) was found (p > 0.05). Subgroup analyses showed that high expression of miR-17-92 family was associated with poor OS (adjusted HRs = 1.89, 95% CIs: 1.43–2.49, p < 0.00001) and DFS (adjusted HRs = 2.83, 95% CIs: 1.59–5.04, p = 0.0003) among the Asian, and no association was found for the Caucasian (p > 0.05). Besides, the HRs of miR-17-92 family high expression in tissue and serum samples was 1.68 (1.35–2.09) and 2.20 (1.08–4.46) for OS, and 1.73 (0.80–3.74) and 3.37 (2.25–5.02) for DFS. It also found that high expression of miR-17-92 family predicted a poor OS in breast cancer, esophageal squamous cell carcinoma, lymphoma and other cancers. Findings suggest that miR-17-92 family can be an effective predictor for prognosis prediction in cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19096